Ficompa, 4 mg 28 pcs

Seizures, EpilepsyThe drug Faicompa is indicated as an adjunctive treatment for partial seizures in patients with epilepsy aged 12 years and older in the presence or absence of secondary generalized seizures.

Indications

Fycompa is indicated as an adjunct for the treatment of partial seizures in patients with epilepsy aged 12 years and older with or without secondary generalized seizures.

Pharmacological effect

Pharmacotherapeutic group:

Special instructions

Suicidal alertness

Active ingredient

Perampanel

Composition

Active ingredient:

Pregnancy

For women with preserved childbearing potential who do not use contraceptive methods, taking Fycompa is recommended only when absolutely necessary.

Data on the use of perampanel in pregnant women are significantly limited (

Animal studies have shown that perampanel and/or its metabolites are excreted in breast milk. It is unknown whether perampanel is excreted into breast milk in humans, so a risk to the baby cannot be excluded.

Given the benefits of both breastfeeding for the child and therapy for the woman, it is necessary to either stop breastfeeding or refrain from taking/discontinue taking Fycompa during breastfeeding.

Effect on fertility

In animal studies, it was shown that in high doses (30 mg/kg), perampanel prolongs and disrupts the regularity of the estrous cycle, but these changes did not affect fertility and early fetal development. No effect on male fertility was found. The effect of perampanel on human fertility has not been studied.

Contraindications

Hypersensitivity to perampanel or any of the excipients of the drug.

Side Effects

Among patients with partial seizures who received perampanel in all clinical studies conducted, 72% took the drug for 6 months and 43% for more than 12 months.

Interaction

Oral contraceptives

Overdose

Clinical experience with perampanel overdose in humans is limited. In a report of an intentional overdose that could have resulted in doses up to 264 mg, the patient experienced altered consciousness, agitation, and aggressive behavior; recovery was without consequences.

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

4 years

Manufacturer

Eisai, Japan